AUSNUTRIA (01717) announced its annual performance with a net profit attributable to shareholders of 1.78 billion yuan, a decrease of 24.8% year-on-year.
Ausnutria (01717) has released its annual performance report for the year ending December 31, 2025. The company reported revenue of 7.488 billion yuan, a year-on-year increase of 1.2%. Gross profit was 2.893 billion yuan, a year-on-year decrease of 6.9%. Net profit attributable to equity holders was 178 million yuan, a year-on-year decrease of 24.8%. Basic earnings per share were 9.98 cents, and the final dividend per share was 0.05 Hong Kong dollars.
AUSNUTRIA (01717) released its annual performance for the year ending December 31, 2025, with a revenue of 7.488 billion yuan, a year-on-year increase of 1.2%. Gross profit was 2.893 billion yuan, a year-on-year decrease of 6.9%. The net profit attributable to equity holders of the company was 178 million yuan, a year-on-year decrease of 24.8%. Basic earnings per share were 9.98 cents, and the final dividend per share was 0.05 Hong Kong dollars.
The announcement stated that the increase in revenue was mainly due to the significant improvement in the overseas performance of Jiabeiet and the increase in sales of goat cheese following the acquisition of Amalthea (together with its subsidiary companies collectively referred to as the "Amalthea Group") in October 2024.
Related Articles

NC Healthcare (01518) released its annual performance, reporting a net loss of 115 million yuan attributable to shareholders, a turnaround from profit to loss compared to the previous year.

SOFTMEDX (00648) released its annual performance, with a net profit of HK$6.95 million, a decrease of 97.87% year-on-year.

LAI SUN INT'L (00191) announced its interim financial results, with a net loss attributable to shareholders of HK$682 million, representing a 453.4% increase year-on-year.
NC Healthcare (01518) released its annual performance, reporting a net loss of 115 million yuan attributable to shareholders, a turnaround from profit to loss compared to the previous year.

SOFTMEDX (00648) released its annual performance, with a net profit of HK$6.95 million, a decrease of 97.87% year-on-year.

LAI SUN INT'L (00191) announced its interim financial results, with a net loss attributable to shareholders of HK$682 million, representing a 453.4% increase year-on-year.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


